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findings of the original pathology slides and 
clinical outcomes. Gross tumour architecture 




Papillary growth was identified in 983 
patients (72.2%) and sessile growth in 380 
(27.8%). The sessile growth pattern was 
associated with higher tumour grade, more 
advanced stage, lymphovascular invasion, 








 0.001). In multivariable Cox regression 
analyses that adjusted for the effects of 
pathological stage, grade and lymph node 
status, tumour architecture (sessile or 
papillary) was an independent predictor 
















 0.001). Adding tumour architecture 
increased the predictive accuracy of a model 
that comprised pathological stage, grade 
and lymph node status for predicting cancer 
recurrence and cancer-specific death by a 
minimal but statistically significant margin 













The tumour architecture of UTUC is 
associated with established features of 
biologically aggressive disease, and more 
importantly, with prognosis after radical NU. 
Including tumour architecture in predictive 
models for disease progression should be 
considered, aiming to identify patients 





urothelial carcinoma, urinary tract cancer, 
architecture, recurrence, survival
Study Type – Prognosis (retrospective 
cohort study)




To assess whether tumour architecture can 
help to refine the prognosis of patients 
treated with nephroureterectomy (NU) for 
urothelial carcinoma (UC) of the upper 
urinary tract (UT), as the prognostic value of 





The study included 1363 patients with UTUC 
and treated with radical NU at 12 centres 
worldwide. All slides were re-reviewed 
according to strict criteria by genitourinary 




Upper tract urothelial carcinoma (UTUC) is 









of renal tumours [1]. Presently, radical 
nephroureterectomy (RNU) with removal of a 
bladder cuff is the primary treatment for 
UTUC. Of patients with UTUC, 20–55% 
develop metastases and eventually die from 
their disease [1–4]. Tumour stage, grade, 
lymph node (LN) invasion and extent of 
surgery have been established as significant 
prognostic factors [4–6].
The prognostic importance of tumour 
architecture (papillary vs sessile) has not 
been conclusively investigated in UTUC. 
In bladder UC, sessile tumour architecture 
has been suggested to predict a worse 
outcome [7]. The aim of the current study 
was to assess whether tumour architecture 
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The study was approved by an institutional 
review board, with all participating sites 
providing the necessary institutional data-use 
agreements before starting the study. In all, 
12 academic centres worldwide provided 
data; a computerized databank was generated 
for data transfer. After combining the 
datasets, reports were generated for each 
variable to identify data inconsistencies 
and other data integrity problems. Through 
regular communication with all sites, all 
identified anomalies were resolved before 
data analysis. Before the final analysis the 
database was ‘frozen’ and the final dataset 
was produced for the current analysis. This 
study comprised 1363 patients who had RNU 
with a bladder cuff between 1987 and 2007.
All surgical specimens were processed 
according to standard pathological 
procedures, and all slides were re-reviewed 
by genitourinary pathologists according to 
identical strict criteria and who were unaware 
of the clinical outcomes. Tumours were 
staged pathologically according to the 2002 
TNM classification of the American Joint 
Committee on Cancer, and tumours were 
graded according to the 1998 WHO/
International Society of Urologic Pathology 
consensus classification. Tumour architecture 
(papillary vs sessile) was defined based on the 
predominant feature [7].
Patients were generally followed every 3–
4 months for the first year after RNU, every 
6 months from 2–5 years, and annually 
thereafter. The follow-up consisted of a 
history, physical examination, routine 
blood and serum chemistry studies, urinary 
cytology, chest radiography, cystoscopic 
evaluation of the urinary bladder, and 
radiographic evaluation of the contralateral 
upper urinary tract. Elective bone scans, chest 
CT or MRI were used when clinically indicated. 
The mean (median, range) follow-up for these 
patients was 51.1 (35.8, 1.2–250) months.
The cause of death was determined by 
the treating physicians, by chart review 
corroborated by death certificates, or by 
death certificates alone. Perioperative 
mortality (any death within 30 days of 
surgery or before discharge) was censored at 
time of death for urothelial disease-specific 
survival analyses.
The chi-squared test was used to evaluate the 
association between categorical variables. 
Differences in variables with a continuous 
distribution across dichotomous categories 





test. Univariable recurrence and survival 
probabilities after RNU were estimated 












No. of patients 1363 938 380






Men 921 (67.6) 673 (73.1) 248 (26.9)
Women 442 (32.4) 310 (70.1) 132 (29.9) 0.273†
Pathological T stage
T0/Ta/Tis 301 (22.1) 274 (91) 27 (9)
T1 299 (21.9) 273 (91.3) 26 (8.7)
T2 252 (18.5) 192 (76.2) 60 (23.8)
T3 443 (32.5) 233 (52.6) 210 (47.4)






Low 495 (36.3) 466 (94.1) 29 (5.9)






Unknown 788 (57.8) 586 (76) 187 (24)
Negative 440 (32.3) 340 (75) 115 (25)






Negative 1025 (75) 818 (79.8) 207 (20.2)






Negative 972 (71) 760 (78.2) 212 (21.8)










-test; †Pearson chi-square test.
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and multivariable Cox regression models 
addressed time to recurrence and disease-
specific mortality after RNU. In all models, 
proportional hazards assumptions were 
systematically verified, using the 
Grambsch-Therneau residual-based test. 
The change in predictive accuracy 
resulting from adding the variable of 
interest to standard predictor variables was 
quantified with Harrell’s concordance index 
[8,9]. Internal validation was performed using 
200-bootstrap re-samples [8,9]. Predictive 
accuracy estimates were expressed as 
proportions and compared with the Mantel-




 values are two-









 values are given; no 








Table 1 lists the clinicopathological 
characteristics of the 1363 patients; 
papillary architecture was found in 983 
patients (72.2%) and sessile architecture 
in 380 (27.8%). Regional lymphadenectomy 
was generally performed in patients 
with enlarged lymph nodes on 
preoperative axial imaging or with 
adenopathy detected during intraoperative 
examination. As such, 58% of patients in this 
cohort did not have a lymphadenectomy 
(pNx).
Sessile architecture was associated with 
advanced pathological stage, higher 
tumour grade, metastasis to lymph 
nodes, lymphovascular invasion (LVI) and 









Disease recurrence is shown in Table 2; the 
5-year recurrence-free survival (RFS) 
estimate was 70% (Fig. 1A). The median 
RFS for papillary vs sessile UTUC was 132 








 0.001). The 
5- and 10-year RFS rates were significantly 
lower for sessile than for papillary tumours 
(40% and 32% vs 77% and 75%, respectively; 
Fig. 1B). On univariable and multivariable 
analyses, pathological stage, grade, LN status 









Table 2) were associated with disease 
recurrence. The predictive accuracy of the 
base model for disease recurrence that 
included pathological stage, grade and 
LN status was 78.4%; adding tumour 
architecture improved the predictive accuracy 









Cancer-specific survival (CSS) is also shown in 
Table 2; the 5-year CSS estimate was 74% 
(Fig. 1C). The median CSS for papillary vs 
sessile UTUC was 132 vs 45 months. The 5- 
and 10-year CSS rates were lower for sessile 
than for papillary tumours (45% and 34% 
vs 80% and 77%, respectively; Fig. 1D). On 
univariable amd multivariable analyses, 
pathological stage, grade, LN status and 

















 0.003; Table 2). The 
predictive accuracy of the base model for CSS 
was 78.3%; adding tumour architecture 
improved the predictive accuracy of this base 












As in UC of the urinary bladder, about two-
thirds of patients treated with RNU for UTUC 
have a papillary growth pattern and a third 
a sessile growth pattern. A solid or sessile 
cancer is highly suggestive of muscle-invasive 
disease in bladder cancer [7,10]. However, to 
our knowledge, there is no study evaluating 
the predictive accuracy of the macroscopic 
description of tumour architecture with 
outcomes in patients with UTUC. Sessile 
tumour growth was associated with 
established features of biologically 
aggressive UTUC, e.g. higher tumour grade, 
advanced stage, LVI and LN metastasis. More 
importantly, tumour architecture was an 
independent predictor of cancer recurrence 
and cancer-specific mortality after RNU. 




Univariable and multivariable Cox regression analyses predicting disease recurrence and 




















T1 vs T0/Ta/Tis 1.72; 0.05 1.38; 0.25




























































 tumour architecture 78.9





















T1 vs T0/Ta/Tis 1.51; 0.19 1.29; 0.42






















































 tumour architecture 79.3
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marginally but significantly the accuracy of 
a model based on established pathological 
features for predicting both cancer recurrence 
and cancer-specific death.
Tumour architecture was independently 
associated with clinical outcomes after RNU; 
while both papillary and sessile tumours can 
be invasive and high-grade, leading to disease 
recurrence, sessile tumours were more likely 
to behave aggressively. While small UTUCs are 
rarely muscle-invasive, having a nonpapillary 
architecture (sessile form) can predict muscle 
invasion. As such, 44% of papillary tumours 
vs 86% of sessile tumours were muscle-
invasive. At 5 years after RNU, 40% of 
patients with papillary vs 77% with sessile 
tumours had disease recurrence. Langner 
et al. [11] showed that infiltrative UTUC were 
of higher stage and grade (both P < 0.001). In 
multivariable analyses only tumour stage 
and tumour architecture were independent 
markers for metastasis-free survival. Usually 
sessile tumours also have a higher grade, 
because most infiltrative UC are high grade 
[12].
Although cancer architecture only marginally 
improved the predictive accuracy for disease 
recurrence and CSS after RNU it remained 
statistically significant. This feature is readily 
available, as it is generally reported in 
standard pathology reports. Moreover, the 
greatest advantage of this feature is that 
it is readily available during ureteroscopic 
evaluation and correlates very well with stage 
and grade, which are difficult to assess during 
endoscopic examination. Thus, it could be a 
useful marker in selected patients to guide 
conservative vs extirpative further therapy. 
Therefore its inclusion in predictive tools for 
UTUC should be considered. Such predictive 
tools could be helpful in patient counselling, 
panning the follow-up, and clinical trial 
design.
There are several limitations to the present 
study. First there are limitations inherent 
in retrospective analyses. In addition, the 
present patients had RNU by several surgeons 
at many sites, and had their specimens 
evaluated by many pathologists. While 
prognostic factors might perform well in the 
selected group of patients operated by one 
surgeon, it remains to be determined whether 
these are applicable to the greater population 
of patients with UTUC. All specimens were 
re-examined by dedicated genitourinary 
pathologists according to strict criteria agreed 
on by all participating pathologists. Thus, the 
multi-institutional nature of the study and 
the use of ‘local’ pathological interpretation 
might make the results more relevant and 
applicable in both the academic and 
community settings.
In conclusion, gross tumour architecture of 
UTUC is associated with established features 
of aggressive disease and clinical outcomes 
after RNU. While it is an independent risk 
factor for disease recurrence and cancer-
specific mortality, considering this variable 
increases the predictive accuracy only 
marginally. After validation, inclusion 
of tumour architecture into predictive 
models for disease progression should be 
considered, aiming to identify patients who 
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